News
News

The latest updates from AFAR.

AFAR Experts in the News: Kirkland, LeBrasseur, and Musi’s research in EBioMedicine on promising findings from first human trial of senolytic drugs.

Jan 9
2019

AFAR Experts in the News: Kirkland, LeBrasseur, and Musi’s research in EBioMedicine on promising findings from first human trial of senolytic drugs. View MoreBACK

On January 5, 2019, EBioMedicine (a publication of The Lancet) published research co-authored by AFAR experts James L. Kirkland, MD, PhD, Nathan LeBrasseur, PhD, and Nicholas Musi, MD sharing promising findings from the first human trials of senolytic drugs.


Dr. Kirkland is AFAR’s Board President-Elect and a 2012 Glenn/AFAR Breakthroughs in Gerontology Award recipient.

Dr. LeBrasseur is a 2002 Glenn/AFAR Scholarships for Research in the Biology of Aging recipient.


Dr. Musi is 2007 Beeson Scholar and has served on AFAR’s National Scientific Advisory Council. Additionally, Dr. Musi is co-leader of the Healthspan and Functional Assessment Core at the Nathan Shock Center at UT Health San Antonio, one of the NIA’s six Nathan Shock Centers of Excellence in the Basic Biology of Aging, for which AFAR serves as the Coordinating Center.


The article is also co-authored by Stephen Kritchevsky, PhD, who is co-Principal Investigator/Director of the NIA’s Research Centers Collaborative Network, for which AFAR serves as the Coordinating Center with Wake Forest School of Medicine.


Read their published research--"Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study”--here and a related press release on Science Daily here.
 

 





View MoreBACK TO TOP